Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
Glioblastoma is the most common adult primary brain tumor and carries a dismal prognosis. Radiation is a standard first-line therapy, typically deployed following maximal safe surgical debulking, when possible, in combination with cytotoxic chemotherapy. For other systemic cancers, standard of care...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00656/full |
| _version_ | 1819320012634062848 |
|---|---|
| author | Karishma R. Rajani Lucas P. Carlstrom Ian F. Parney Aaron J. Johnson Arthur E. Warrington Terry C. Burns |
| author_facet | Karishma R. Rajani Lucas P. Carlstrom Ian F. Parney Aaron J. Johnson Arthur E. Warrington Terry C. Burns |
| author_sort | Karishma R. Rajani |
| collection | DOAJ |
| description | Glioblastoma is the most common adult primary brain tumor and carries a dismal prognosis. Radiation is a standard first-line therapy, typically deployed following maximal safe surgical debulking, when possible, in combination with cytotoxic chemotherapy. For other systemic cancers, standard of care is being transformed by immunotherapies, including checkpoint-blocking antibodies targeting CTLA-4 and PD-1/PD-L1, with potential for long-term remission. Ongoing studies are evaluating the role of immunotherapies for GBM. Despite dramatic responses in some cases, randomized trials to date have not met primary outcomes. Challenges have been attributed in part to the immunologically “cold” nature of glioblastoma relative to other malignancies successfully treated with immunotherapy. Radiation may serve as a mechanism to improve tumor immunogenicity. In this review, we critically evaluate current evidence regarding radiation as a synergistic facilitator of immunotherapies through modulation of both the innate and adaptive immune milieu. Although current preclinical data encourage efforts to harness synergistic biology between radiation and immunotherapy, several practical and scientific challenges remain. Moreover, insights from radiation biology may unveil additional novel opportunities to help mobilize immunity against GBM. |
| first_indexed | 2024-12-24T11:12:49Z |
| format | Article |
| id | doaj.art-07e9ee7b48d64e3cb1db511d87b0cea3 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-24T11:12:49Z |
| publishDate | 2019-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-07e9ee7b48d64e3cb1db511d87b0cea32022-12-21T16:58:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-02-01810.3389/fonc.2018.00656429617Harnessing Radiation Biology to Augment Immunotherapy for GlioblastomaKarishma R. Rajani0Lucas P. Carlstrom1Ian F. Parney2Aaron J. Johnson3Arthur E. Warrington4Terry C. Burns5Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, United StatesDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, United StatesDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, United StatesDepartment of Immunology, Mayo Clinic, Rochester, MN, United StatesDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, United StatesDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, United StatesGlioblastoma is the most common adult primary brain tumor and carries a dismal prognosis. Radiation is a standard first-line therapy, typically deployed following maximal safe surgical debulking, when possible, in combination with cytotoxic chemotherapy. For other systemic cancers, standard of care is being transformed by immunotherapies, including checkpoint-blocking antibodies targeting CTLA-4 and PD-1/PD-L1, with potential for long-term remission. Ongoing studies are evaluating the role of immunotherapies for GBM. Despite dramatic responses in some cases, randomized trials to date have not met primary outcomes. Challenges have been attributed in part to the immunologically “cold” nature of glioblastoma relative to other malignancies successfully treated with immunotherapy. Radiation may serve as a mechanism to improve tumor immunogenicity. In this review, we critically evaluate current evidence regarding radiation as a synergistic facilitator of immunotherapies through modulation of both the innate and adaptive immune milieu. Although current preclinical data encourage efforts to harness synergistic biology between radiation and immunotherapy, several practical and scientific challenges remain. Moreover, insights from radiation biology may unveil additional novel opportunities to help mobilize immunity against GBM.https://www.frontiersin.org/article/10.3389/fonc.2018.00656/fullradiationglioblastomaGBMPD-1/PD-L1CTLA-4immunotherapies |
| spellingShingle | Karishma R. Rajani Lucas P. Carlstrom Ian F. Parney Aaron J. Johnson Arthur E. Warrington Terry C. Burns Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma Frontiers in Oncology radiation glioblastoma GBM PD-1/PD-L1 CTLA-4 immunotherapies |
| title | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| title_full | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| title_fullStr | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| title_full_unstemmed | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| title_short | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| title_sort | harnessing radiation biology to augment immunotherapy for glioblastoma |
| topic | radiation glioblastoma GBM PD-1/PD-L1 CTLA-4 immunotherapies |
| url | https://www.frontiersin.org/article/10.3389/fonc.2018.00656/full |
| work_keys_str_mv | AT karishmarrajani harnessingradiationbiologytoaugmentimmunotherapyforglioblastoma AT lucaspcarlstrom harnessingradiationbiologytoaugmentimmunotherapyforglioblastoma AT ianfparney harnessingradiationbiologytoaugmentimmunotherapyforglioblastoma AT aaronjjohnson harnessingradiationbiologytoaugmentimmunotherapyforglioblastoma AT arthurewarrington harnessingradiationbiologytoaugmentimmunotherapyforglioblastoma AT terrycburns harnessingradiationbiologytoaugmentimmunotherapyforglioblastoma |